Key Players
Competitive Landscape
Companies in the industry mostly fall in four distinct models: multinational antibiotic portfolios, specialist anti-infective developers, hospital-focused commercialization platforms and territory-based licensing groups. The field remains concentrated around a small set of approved intravenous therapies. Entry depends on completed clinical programs, regulator-defined pathogen claims, stewardship support and dependable hospital distribution.
Commercial activity has moved in two directions since 2025: wider regional access for resistant-pathogen antibiotics and lifecycle expansion into pediatric HAP/VAP. ADVANZ PHARMA’s European Zevtera sales triggered a partner milestone reported in January 2025. Shionogi’s pediatric Fetroja application was accepted by the FDA in July 2026 with a February 2027 action date. Hospital price remains relevant, but formulary teams first compare organism coverage, resistance evidence and infusion requirements.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Basilea reported in January 2025 that European Zevtera sales through ADVANZ PHARMA crossed a partner milestone threshold. | Hospitals continue purchasing intravenous HAP therapy with MRSA-active coverage. | Regional licensees increasingly carry commercial responsibility for established hospital antibiotics. | European formulary expansion and supply revenue for HAP excluding VAP. |
| Shionogi reported in February 2025 that partner JEIL obtained South Korean approval for Fetroja after a program that included a nosocomial pneumonia trial. | Hospitals need additional options for carbapenem-resistant Gram-negative infections. | Country approvals extend specialist antibiotics through local commercial partners. | Hospital access in South Korea for resistant-infection treatment. |
| Shionogi’s pediatric Fetroja sNDA was accepted by the FDA in July 2026 with a February 23, 2027 action date. | Pediatric hospitals need labeled dosing for serious Gram-negative infections. | Approved adult HAP/VAP assets are moving into pediatric lifecycle programs. | Pediatric hospital access if the FDA approves the supplement. |
Merck, Pfizer, Innoviva Specialty Therapeutics, Allecra Therapeutics and Menarini compete through approved labels, hospital sales infrastructure or licensed development rights without another dated event in this section.
Source: Future Market Insights, Hospital-Acquired Pneumonia Market and Hospital-Acquired Infection Control Market Reports, 2026-2036.
Merck and Shionogi cover direct Gram-negative HAP/VAP therapy in the United States. Innoviva adds Acinetobacter-specific treatment and a dedicated hospital platform. Pfizer, ADVANZ and Allecra cover established or newly approved beta-lactam combinations in Europe. Basilea and Menarini extend the field through licensed regional programs.
Who leads the Hospital-Acquired Pneumonia Market?
Merck, Shionogi and Innoviva hold direct USA HAP/VAP labels. ADVANZ and Allecra add approved European HAP/VAP coverage. Their positions differ by pathogen scope, indication wording and partner reach, so no company leads every territory.
Which suppliers have documented HAP or VAP approvals?
Merck’s Recarbrio, Shionogi’s Fetroja, Innoviva’s Xacduro and ADVANZ/Allecra’s Exblifep carry direct HAP or VAP indications in their approved territories. Pfizer’s Zavicefta includes adult HAP and VAP in Europe, while Basilea’s Zevtera excludes VAP in its HAP markets.
Which companies provide therapies for resistant Gram-negative hospital pneumonia?
Recarbrio covers specified susceptible Gram-negative organisms, while Fetroja addresses several difficult Gram-negative pathogens. Xacduro is limited to susceptible Acinetobacter baumannii-calcoaceticus complex. Exblifep combines cefepime with enmetazobactam for severe infections that include HAP and VAP in Europe.
Which suppliers serve North America and Europe?
Merck and Innoviva commercialize direct HAP/VAP products in the United States. Pfizer, ADVANZ, Allecra and Basilea serve European hospital markets through owned rights or licensing partners. Shionogi spans the United States, Europe and selected Asia-Pacific markets. Menarini holds development-stage rights across 96 countries.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Merck & Co., Inc. | United States | Recarbrio intravenous therapy for adult and pediatric HABP/VABP; the pediatric supplement was approved in December 2025. |
| Pfizer Inc. | Europe and international markets | Zavicefta intravenous therapy includes adult HAP and VAP in Europe. Pfizer also maintains established hospital anti-infective distribution. |
| Shionogi & Co., Ltd. | United States, Europe, Japan and partner markets | Fetroja/Fetcroja cefiderocol addresses resistant Gram-negative infections. The USA adult label includes HAP/VAP, and the pediatric sNDA was accepted in July 2026. |
| Innoviva Specialty Therapeutics, Inc. | United States and licensed international territories | Xacduro intravenous therapy treats adult HAP/VAP caused by susceptible Acinetobacter baumannii-calcoaceticus complex. |
| Basilea Pharmaceutica Ltd. | Europe and selected international markets | Zevtera/Mabelio intravenous therapy covers adult HAP excluding VAP in approved markets. Partner-led commercialization supports regional access. |
| ADVANZ PHARMA Holdco Limited | European Union, United Kingdom, Switzerland and Norway | Exblifep intravenous therapy includes HAP/VAP. ADVANZ also commercializes Zevtera in parts of Europe. |
| Allecra Therapeutics GmbH | Europe and licensed partner territories | Allecra developed cefepime/enmetazobactam and licensed European supply and commercialization to ADVANZ. |
| A. Menarini Industrie Farmaceutiche Riunite S.r.l. | Development rights across 96 countries | Cefepime-taniborbactam commercial rights remain development-stage for hospital-acquired and ventilator-associated bacterial pneumonia. |
Research Methodology
The companies above illustrate market structure rather than rank suppliers. Inclusion requires current evidence of an approved HAP/VAP therapy, a licensed hospital-pneumonia program or hospital commercialization rights tied to the defined market. Evidence comes from regulator records, corporate releases, filings and clinical-trial records. Product approvals belong to the named medicine and territory. Development rights do not equal approval. The 64.0% antibiotic share remains an FMI estimate for 2026.
